Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
University of Chicago
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02046421CT.gov Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT01349959CT.gov Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer | — | Completed | — | — | — |
NCT01288261CT.gov Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01281150CT.gov Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT01276496CT.gov Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT01245205CT.gov Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer | — | Completed | — | — | — |
NCT01104259CT.gov Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01145430CT.gov Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01084057CT.gov Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01131234CT.gov Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
Show 11 more trialsShow fewer
NCT00937482CT.gov Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00699491CT.gov Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00450879CT.gov Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery | — | Terminated | — | — | — |
NCT00348699CT.gov AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00244881CT.gov A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) | — | Completed | — | — | — |
NCT00095888CT.gov 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00089362CT.gov Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | — | Completed | — | — | — |
NCT00070252CT.gov Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer | — | Completed | — | — | — |
NCT00063934CT.gov Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer | — | Terminated | — | — | — |
NCT00039455CT.gov Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00006228CT.gov Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Male Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cediranib (this asset) | University of Chicago | P2 | BB · 71 |
| Cyclophosphamide | Wake Forest University Health Sciences | P2 | BBB |
| Irinotecan | University of California, Irvine | P2 | BBB |
| Nivestim | University of Washington | P2 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P2 | BBB |
| Tamoxifen | Jose Pablo Leone | P3 | BB |
| Sargramostim | University of Washington | P2 | BB |
| Trastuzumab | H. Lee Moffitt Cancer Center and Research Institute | P3 | BB |
| Capecitabine | Jonsson Comprehensive Cancer Center | P2 | BB |
+42 more in the Male Breast Carcinoma cohort
Other indications for Cediranib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gliosarcoma | — | P2 | BBB · 76 |
| Metastatic Melanoma | — | P2 | BBB · 73 |
| Adult Glioblastoma | — | P2 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cediranib in Male Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/cediranib-male-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →